Tabula Rasa HealthCare (TRHC) Rating Increased to Buy at BidaskClub

Tabula Rasa HealthCare (NASDAQ:TRHC) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday.

A number of other research firms also recently commented on TRHC. Zacks Investment Research downgraded Tabula Rasa HealthCare from a “strong-buy” rating to a “hold” rating in a report on Friday, November 10th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $29.00 target price (up previously from $20.00) on shares of Tabula Rasa HealthCare in a report on Wednesday, September 20th. UBS lifted their target price on Tabula Rasa HealthCare from $18.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, August 30th. Wells Fargo & Company lifted their target price on Tabula Rasa HealthCare from $21.00 to $27.00 and gave the stock a “market perform” rating in a report on Thursday, October 19th. Finally, ValuEngine raised Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a report on Saturday, September 30th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $29.00.

Shares of Tabula Rasa HealthCare (NASDAQ TRHC) opened at $29.39 on Thursday. The company has a current ratio of 0.73, a quick ratio of 0.66 and a debt-to-equity ratio of 0.47. Tabula Rasa HealthCare has a twelve month low of $11.59 and a twelve month high of $36.80. The company has a market capitalization of $526.72, a PE ratio of -117.56, a P/E/G ratio of 24.85 and a beta of 2.81.

Tabula Rasa HealthCare (NASDAQ:TRHC) last released its earnings results on Monday, November 6th. The company reported $0.08 EPS for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.02. Tabula Rasa HealthCare had a negative return on equity of 5.58% and a negative net margin of 2.27%. The firm had revenue of $33.27 million during the quarter, compared to the consensus estimate of $31.76 million. During the same quarter in the previous year, the company posted $0.06 earnings per share. The company’s revenue was up 37.6% compared to the same quarter last year. analysts expect that Tabula Rasa HealthCare will post 0.05 EPS for the current fiscal year.

In other Tabula Rasa HealthCare news, insider Orsula V. Knowlton sold 8,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 18th. The stock was sold at an average price of $26.68, for a total value of $213,440.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bruce Luehrs sold 269,000 shares of the business’s stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $25.85, for a total value of $6,953,650.00. The disclosure for this sale can be found here. Insiders sold 1,099,180 shares of company stock valued at $28,435,203 over the last three months. 45.80% of the stock is currently owned by corporate insiders.

A number of large investors have recently made changes to their positions in the business. Paradigm Capital Management Inc. NY lifted its holdings in Tabula Rasa HealthCare by 3.4% in the third quarter. Paradigm Capital Management Inc. NY now owns 80,000 shares of the company’s stock valued at $2,139,000 after acquiring an additional 2,644 shares during the period. TIAA CREF Investment Management LLC increased its position in shares of Tabula Rasa HealthCare by 108.5% in the first quarter. TIAA CREF Investment Management LLC now owns 8,131 shares of the company’s stock valued at $110,000 after buying an additional 4,232 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Tabula Rasa HealthCare by 79.8% in the third quarter. Wells Fargo & Company MN now owns 12,768 shares of the company’s stock valued at $341,000 after buying an additional 5,668 shares in the last quarter. California State Teachers Retirement System increased its position in shares of Tabula Rasa HealthCare by 60.2% in the second quarter. California State Teachers Retirement System now owns 16,500 shares of the company’s stock valued at $248,000 after buying an additional 6,200 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Tabula Rasa HealthCare by 47.2% in the second quarter. Bank of New York Mellon Corp now owns 19,412 shares of the company’s stock valued at $293,000 after buying an additional 6,228 shares in the last quarter. 31.85% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Tabula Rasa HealthCare (TRHC) Rating Increased to Buy at BidaskClub” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/12/23/tabula-rasa-healthcare-trhc-rating-increased-to-buy-at-bidaskclub.html.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit